Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of DSP-5423P in schizophrenia
NCT02335658Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- Dec 2014
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of blonanserin in schizophrenia, sponsored by Sumitomo Pharma. Started Dec 2014; status: completed.
02
Drugs
blonanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02335658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02335658.